This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts?
by Zacks Equity Research
Let's look at five pharma and drug companies, MRK PFE, LLY, AMGN and BMY, which are scheduled to release their fourth-quarter 2024 results later this week.
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug
by Zacks Equity Research
The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of BIIB/Eisai's Leqembi in the EU for early AD.
Curious about Lilly (LLY) Q4 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Lilly (LLY) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Eli Lilly Stock Before Q4 Earnings: To Buy or Not to Buy?
by Kinjel Shah
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
Do Options Traders Know Something About Lilly (LLY) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Lilly (LLY) stock based on the movements in the options market lately.
Top Analyst Reports for Alibaba, Airbnb & Royal Caribbean Cruises
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), Airbnb, Inc. (ABNB) and Royal Caribbean Cruises Ltd. (RCL), as well a micro-cap stock DallasNews Corporation (DALN).
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viking Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
Since VKTX is devoid of marketed drugs, investors will focus on pipeline updates when it reports Q4 results next week.
Should AstraZeneca Stock Be in Your Portfolio Pre-Q4 Earnings?
by Zacks Equity Research
AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Eli Lilly (LLY) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $804.99, marking a -0.39% move from the previous day.
How to Play NVO Stock After New Drug's Success in Obesity Study
by Ahan Chakraborty
The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh in on the stock's growth prospects.
Merck Q4 Earnings Coming Up: Buy, Hold or Sell MRK Stock Now?
by Kinjel Shah
When Merck reports fourth-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.
Here's How to Play Pfizer Stock Before Q4 Earnings Release
by Kinjel Shah
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the fourth quarter.
BIIB Secures FDA Nod for Monthly Maintenance Dosing of Alzheimer's Drug
by Zacks Equity Research
The FDA's approval is based on simulation data from multiple studies showing that maintenance dosing with Biogen???s Leqembi every four weeks prolongs biomarker benefits.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
by Zacks Equity Research
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Zacks Analyst Blog Eli Lilly, Exxon Mobil, Costco and Flanigan's
by Zacks Equity Research
Eli Lilly, Exxon Mobil, Costco and Flanigan's are included in this Analyst Blog.
Eli Lilly (LLY) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Eli Lilly (LLY) closed at $753.98 in the latest trading session, marking a +1.57% move from the prior day.
Top Analyst Reports for Eli Lilly, Exxon Mobil & Costco
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Exxon Mobil Corporation (XOM) and Costco Wholesale Corporation (COST), as well a micro-cap stock Flanigan's Enterprises, Inc. (BDL).
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
by Ahan Chakraborty
Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney diseases as well certain brain ailments.
Johnson & Johnson (JNJ) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 2% and 0.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
5 Stocks on Sale: Values or Traps?
by Tracey Ryniec
Tracey discusses 5 stocks that have had big market sell-offs. Should they be on your watch list?
NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts
by Zacks Equity Research
Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price negotiations in 2025.
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
by Kinjel Shah
J&J offers to buy ITCI for $14.6 billion. LLY announces disappointing preliminary sales numbers for the fourth quarter.